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additional surrogate markers such as the value of a during
treatment second tympanocentesis, the impact of the study
medication on the nasopharygeal ﬂora and more recently
the parents and children response to speciﬁc questions as a
way to evaluate time to clinical resolution between agents
or against placebo. Importantly, clinical trials have focus on
those children that most likely require antimicrobial therapy
either because they have a recurrent otitis media or they are
therapeutic failures to standard OM therapy making these
two set of patients at high risk of having a resistant pathogen
in the affected middle ear. Completed clinical trials have
been presented or published in peer review journals with the
main focus been the impact of these new compounds against
resistant S. pneumoniae strains and against the other target
MEF pathogens. In this regard, some of the trial that were
performed and that will be described in detail in the pre-
sentation, include a study using single dose azythormycin,
a regimen approved by the FDA but with current large lim-
itation because of the rates of macrolide resistance; a high
dose twice a day cefdinir that showed disappointing results
against resistant S. pneumoniae and for H. inﬂuenzae; a
new azythromycin formulation used as a larger dose that
showed low eradication rates against macrolide resistant
S. pneumoniae but a better eradication rate against H.
inﬂuenzae; a recently completed trial with an oral carpa-
penem (faropenem) [results pending] and multiple trials
with two promising quinolones for these problematic chil-
dren presented as a pediatric formulation (gatiﬂoxacin and
levoﬂoxacin) that showed a tremendous success but whose
programs were put on hold by the sponsors. A pediatric
program with telithromycin, a new ketolide with excellent
invitro activity against penicillin and macrolide resistant
S. pneumoniae was also put on hold by the sponsor. Cur-
rently the number of trials for otitis media are extremely
limited however there are children with problematic antimi-
crobial resistant pathogens that need research programs in
this area.
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It is well recognized that appropriately chosen antibiotics
enhance bacteriologic eradication in culture-positive AOM.
It is also established that if bacteriologic eradication does
not occur within 3—5 days of treatment, the risk of clinical
failure at the end of the treatment increases ∼ 5 fold. How-
ever, even with the 5-fold increase, over 50% of those from
whom organisms were not eradicated after 3—5 days are still
doing well at the end of treatment. New evidence demon-
strates that among those who, despite failure of eradication
after 3—5 days of treatment, have clinical improvement or
cure at the end of treatment, recurrence of AOM occurs 35%
more frequently than among those with eradication. Fur-
thermore, in these cases only 34% will have new organisms,
vs. 64% among those from whom bacteria were eradicated.
New evidence also shows that nasopharyngeal (NP) carriage
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t initiation and/or at end of treatment is an independent
ajor determinant of the outcome of AOM, with an indepen-
ent additional role to that of MEF organisms. Antibiotics
ere shown to modify NP carriage at the end of treatment
nd thus play a major role in determining the nature of
he following AOM in children. Thus, although the long term
eneﬁts of antibiotic use in AOM are not proven, the short
erm problems were demonstrated. This should be carefully
eighted when deciding to treat a child with AOM.
oi:10.1016/j.ijid.2008.05.141
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elayed prescribing can take many forms but the Dutch
riginally developed the policy: their guidance was for no
rescription for AOM unless there was signiﬁcant otaligia
nd/or fever 72 hours after seeing the doctor, or if a pro-
onged discharge developed. They have shown in a large
ohort study that if such an approach is used there are likely
o be very few cases of complications. Delayed prescrib-
ng can help rationalise antibiotic use (with reductions in
ntibiotic use from 50—75%); changes beliefs in antibiotics
since prescribing antibiotics probably fuels a vicious circle
f belief in antibiotics, subsequent reattendance, further
ntibiotic use etc.; achieves acceptable symptom control;
nd provides a back up and rapid access to antibiotics where
here is uncertainty about which children will not recover
uickly. There is weak ecological evidence from the UK and
uropean studies that either localities or countries that have
ower prescribing of antibiotics have higher admission rates
or mastoiditis. Even assuming such ecological data does
rovide secure evidence of a genuine problem, the data sug-
ests that several thousand prescriptions would be required
o prevent one case of mastoiditis in afﬂuent developed
opulations. The alternatives to delayed prescribing are all
roblematic: not to prescribe at all which is probably less
afe; to prescribe in most or all cases which will lead to
ide effects, antibiotic resistance, and possibly more com-
lications associated with antibiotic resistance; or to target
ntibiotics those likely to suffer prolonged illness or adverse
vents - but few clinical studies demonstrate such at risk
roups, nor the beneﬁt of antibiotics in such groups. Delayed
rescribing can either be implemented in a number of ways
commonly by giving parents access to a prescription with
lear guidance, or not to prescribe but advise patients to
eturn for review if they are getting worse or not improving.
he latter option provides the clinician with more control,
ut may result in higher reconsultation rates, and for no
lear beneﬁt.
Conclusion: Based on current evidence delayed pre-
cribing has its place. If parents are provided with clear
nformation - about the timing of antibiotic use, and what
hould trigger review, it is acceptable to parents, is reason-
bly safe, and provide a signiﬁcant help in the battle against
ntibiotic resistance.
oi:10.1016/j.ijid.2008.05.142
